For research use only. Not for therapeutic Use.
Neridronic acid (Cat.No:I008279), also known neridronate, is a bisphosphonate. In Italy it is used to treat Osteogenesis imperfecta and Paget/’s disease of bone. Neridronic acid treatment has been reported to be effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy and bone metastasis. Neridronic acid has been developed only for parenteral use, and it is the only one used as intramuscular injection.
| Catalog Number | I008279 |
| CAS Number | 79778-41-9 |
| Synonyms | Neridronate; Neridronic acid; Nerixia.;(6-Amino-1-hydroxyhexylidene)diphosphonic acid |
| Molecular Formula | C6H17NO7P2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid |
| InChI | InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14) |
| InChIKey | PUUSSSIBPPTKTP-UHFFFAOYSA-N |
| SMILES | C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN |
| Reference | </br>1:Neridronic acid for the treatment of bone metabolic diseases. Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S.Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1305-11. doi: 10.1517/17425250903029190. Review. PMID: 19761412 </br>2:Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures. Nicolin V, Bareggi R, Baldini G, Bortul R, Martinelli B, Narducci P.Acta Histochem. 2007;109(5):397-402. Epub 2007 Jun 15. PMID: 17574655 |
